- 中文名稱
Anti-Human VEGF-A
- 英文名字
- Anti-Human VEGF-A
- 供應(yīng)商
- ReliaTech
- 產(chǎn)品貨號
- 101-M57
- 產(chǎn)品報價
- ￥詢價/100ug
- 產(chǎn)品說明書
- 點(diǎn)擊查看
- 購買方式
- 90%產(chǎn)品中國有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868
- 產(chǎn)品新聞
- 背景資料
- Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors.
- 應(yīng)用類型
- WB, IHC (P)
- 免疫原
- 該Anti-Human VEGF-A的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 來源宿主
- 該Anti-Human VEGF-A的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 反應(yīng)性
- 該Anti-Human VEGF-A的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。
- 保存建議
- 該Anti-Human VEGF-A的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。溶解建議：Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.
- 其他
- ReliaTech全稱為受體配體技術(shù)有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國不倫瑞克，是一家后基因組生物技術(shù)公司。ReliaTech主要專注于受體和配體的發(fā)現(xiàn)與研究。此外，ReliaTech也開發(fā)應(yīng)用于血管與淋巴管生成研究的相關(guān)高品質(zhì)試劑。目前ReliaTech提供近2800款產(chǎn)品，產(chǎn)品線主要包括重組蛋白(細(xì)胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。
- 注意
-
該頁面的中文產(chǎn)品信息的翻譯，僅供參考。準(zhǔn)確的產(chǎn)品信息請以廠家的英文說明書為準(zhǔn)。下單前，請瀏覽說明書確認(rèn)。
-
